Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646240 · ClinicalTrials.gov registry record · Phase 1
ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03646240 is a Phase 1 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 14 participants.
The verdict
NCT03646240, a Phase 1 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a prospective, single-center, phase 1 safety study to investigate the safety, tolerability, seizure control, and quality of life in participants with medically-refractory epilepsy who failed epilepsy surgery. These participants will have continued seizures despite being at least 3 months post-epilepsy surgery (resective surgery with an intent to cure).
Interventions
- DRUG ABI-009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03646240
The ClinicalTrials.gov registry entry for NCT03646240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-009 is the first listed.
NCT03646240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03646240 about?
NCT03646240 is a clinical study titled "ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)". This is a prospective, single-center, phase 1 safety study to investigate the safety, tolerability, seizure control, and quality of life in participants with medically-refractory epilepsy who failed epilepsy surgery. These participants will have continued seizures despite being at least 3 months pos...
What is the current status of trial NCT03646240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2018-07-31. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03646240?
The interventions under investigation include: ABI-009 (DRUG).
Who is sponsoring clinical trial NCT03646240?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.